Press Release: Novartis: World's largest -2-

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 1 billion people globally

and we are finding innovative ways to expand access to our latest

treatments. About 125 000 people of more than 140 nationalities work at

Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

http://twitter.com/novartis

For Novartis multimedia content, please visit

www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

[1] Data on file. August 2018.

[2] Dementia fact sheet December 2017; World Health Organization:

www.who.int/news-room/fact-sheets/detail/dementia. Accessed August 2018.

[3] ClinicalTrials.gov:

//clinicaltrials.gov/ct2/results?recrs=ab&cond=Alzheimer+Disease&term=&cntry=&

https://clinicaltrials.gov/ct2/results?recrs=ab&cond=Alzheimer+Disease&term=&cntry=&state=&city=&dist

state=&city=&dist=. Accessed August 2018.

[4] Clin Transl Sci. 2015 Dec; 8(6): 647-654.

[5] Genetic Alliance; District of Columbia Department of Health.

Understanding Genetics: A District of Columbia Guide for Patients and

Health Professionals. Washington (DC): Genetic Alliance; 2010 Feb 17.

Chapter 4, Genetic Counselling. www.ncbi.nlm.nih.gov/books/NBK132139

August 2018.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Gonzalo Linares

Novartis Global Media Relations Novartis Global Drug Development Communications

+41 61 324 7999 (direct) +41 61 324 5117 (direct)

+41 79 593 4202 (mobile) +41 79 386 7432 (mobile)

eric.althoff@novartis.com gonzalo.linares@novartis.com

Angela Fiorin

Novartis Global Pharma Communications

+ 41 61 324 8631 (direct)

+ 41 79 752 6955 (mobile)

angela.fiorin@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2216459/865698.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

September 17, 2018 16:30 ET (20:30 GMT)